Australian drug development company Kazia Therapeutics Limited (NASDAQ:KZIA) on Monday announced the sale of all intellectual property and trademark rights for Cantrixil to Swedish development company Vivesto AB (STO:VIVE) for USD1m.
This agreement provides Kazia with non-dilutive funding to support its proprietary, clinical-stage pipeline.
Vivesto previously licensed the global development and commercialisation rights for Cantrixil from Kazia in March 2021. Initially intended for ovarian cancer, Vivesto has shifted its focus to preclinical exploration of Cantrixil for haematological cancers.
Cantrixil is a legacy asset in Kazia's portfolio, featuring TRXE-002-01, a third-generation benzopyran SMETI inhibitor encapsulated in α-cyclodextrin.
Hoth Therapeutics looks to expand HT-001 US patent coverage
Kazia Therapeutics sells Cantrixil intellectual property and trademarks to Vivesto for USD1m
Langhua Pharmaceutical passes US FDA's on-site inspection
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Dupixent receives approval in Japan as first biologic for COPD treatment
Celltrion adds STEQEYMA to Costco Member Prescription Program
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's